Organization | National Cancer Institute, Slovakia

National Cancer Institute, Slovakia Report issue

Government Phase 2 Phase 3

Founded: Bratislava Slovakia (1946)

Organization Overview

First Clinical Trial

2011

NCT01466231

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

National Cancer Institute, Slovakia

Active Ingredients

Drugs in Phase 3 Trials (4)

autologous microbiome (1 trial)

bifidobacterium animalis (1 trial)

inulin (1 trial)

lactobacillus rhamnosus (1 trial)

Drugs in Phase 2 Trials (11)

avelumab (bavencio) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (2 trials)

copper (cu-7) (1 trial)

disulfiram (antabuse) (2 trials)

everolimus (zortress) (1 trial)

gemcitabine (gemzar) (1 trial)

ifosfamide (ifex) (1 trial)

paclitaxel (taxol) (1 trial)

veliparib (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Diarrhea (Phase 3)

Gonadal Disorders (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Testicular Diseases (Phase 2)

Testicular Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 8
# of Trial APIs: 15